DelveInsight’s, “Pancreatic Cancer Pipeline Insight, 2023,” report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Pancreatic Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Pancreatic Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pancreatic Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Pancreatic Cancer Pipeline Report

 

• DelveInsight’s Pancreatic Cancer Pipeline report depicts a robust space with 120+ active players working to develop 150+ pipeline therapies for Pancreatic Cancer treatment.

 

• The leading Pancreatic Cancer Pipeline Companies includes Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Advaxis, Inc., Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc, Arvinas Inc, Epizyme, Regeneron Pharmaceuticals, Veru Inc., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., Janux Therapeutics, Fusion Pharmaceuticals, Corbus Pharmaceuticals, BioXcel Therapeutics, Onxeo S.A, Ayala Pharmaceuticals, HOOKIPA Pharma, Nuvation Bio, Ambrx, enGene, Jemincare, CellVax Therapeutics, POINT Biopharma, Oncternal Therapeutics, Immunic AG, BioNTech SE, and others.

 

• Promising Pancreatic Cancer Pipeline Therapies includes Pembrolizumab, Talazoparib, ODM-208, ZEN 3694, EPI-7386, RV 001, Adavosertib, Capivasertib, ADXS31-142, TRC253, Nivolumab, LAE001, BR55, ARV-110, Tazemetostat, REGN5678, VERU-111, Abemaciclib, Cabozantinib, LY01005, Tarlatamab, VT-464, BAY2315497, NX-1207, MBM-02, TAVT-45, FOR46, JNJ-78278343, 64Cu-SAR-bisPSMA, DKN-01, HC-1119, ChAdOx1-MVA 5T4, Onvansertib, GT0918, TNB-585, JANX007, 225Ac-PSMA I&T, CRB-701, BXCL701, AsiDNA, ADXS-504, HB-300, NUV-868, ARX517, JMKX002992, Zilovertamab, IMU-935, BNT112, and others.

 

• The Pancreatic Cancer companies and academics that are working to assess challenges and seek opportunities that could influence Pancreatic Cancer R&D. The Pancreatic Cancer pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.

 

To explore more information on the latest breakthroughs in the Pancreatic Cancer Pipeline treatment landscape of the report, click here @ Pancreatic Cancer Pipeline Outlook

 

Pancreatic Cancer Overview

 

Pancreatic cancer refers to the carcinoma arising from the pancreatic duct cells, pancreatic ductal carcinoma. It is the fourth leading cause of cancer deaths in the United States. The 5-year survival rate in the United States ranges from 5% to 15%. The overall survival rate is only 6%. Surgical resection is the only current option for a cure, but only 20% of pancreatic cancer is surgically resectable at the time of diagnosis. More than 90% of adenocarcinoma of the pancreas are duct cell adenocarcinomas with other types being cystadenocarcinoma and acinar cell carcinoma. Two-thirds arise in the pancreatic head; one-third arise in the rest (body and tail of pancreas).

 

Latest Developmental Activities in the Pancreatic Cancer Treatment Landscape

 

• In February 2023, Fusion Pharmaceuticals announced the acquisition from RadioMedix, Inc. of the investigational new drug application for an ongoing Phase II clinical trial (the “TATCIST” trial) evaluating 225Ac-PSMA I&T, a small molecule targeting prostate-specific membrane antigen (“PSMA”) expressed on prostate cancers. Following the closing, the alpha-emitting radiopharmaceutical being evaluated in the TATCIST trial will be known as FPI-2265.

 

• In February 2023, Corbus Pharmaceuticals entered into an exclusive licensing agreement with CSPC Megalith Biopharmaceutical Co., Ltd, a subsidiary of CSPC Pharmaceutical Group Limited for development and commercialization of CRB-701 (SYS6002): a novel clinical-stage antibody drug conjugate (ADC) targeting Nectin-4. The agreement covers exclusive commercialization rights to CRB-701 in the United States, Canada, the European Union (including the European Free Trade Area), the United Kingdom, and Australia. CSPC will retain all rights to SYS6002 in the remaining global markets. Clinical development is underway and will focus on urothelial cancer and other Nectin-4-positive solid tumors, potentially including lung, breast and prostate cancer.

 

• In February 2023, BioXcel Therapeutics, Inc.reported full data from its Phase IIa trial of BXCL701, the Company’s investigational, oral innate immune activator, in combination with KEYTRUDA (pembrolizumab) in small cell neuroendocrine (SCNC) variant metastatic castration-resistant prostate cancer (mCRPC) patients after at least one prior line of chemotherapy for locally advanced or metastatic prostate cancer. Results will be presented in a rapid abstract presentation and a poster presentation at the 2023 American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium on February 16, 2023.

 

• In January 2023, Onxeo S.A. gave an update on the clinical development program of its first-in-class drug candidate AsiDNA. Onxeo has activated its first US clinical study site, Next Oncology San Antonio. This phase I/II multicenter, basket trial intends to assess the safety and preliminary activity of AsiDNA in combination with olaparib in patients with recurrent ovarian, breast, and metastatic castration-resistant prostate cancer (mCRPC) who have progressed on previous PARP inhibitor therapy.

 

• In October 2022, Ayala Pharmaceuticals, Inc. and Advaxis, Inc. entered into a definitive merger agreement. The merger would result in a combined company that will focus predominantly on the development and commercialization of Ayala’s lead program AL102 for the treatment of desmoid tumors and Advaxis’s candidate ADXS-504 in development for prostate cancer.

 

• In October 2022, Janux Therapeutics announced that the first patient had been dosed in Phase I clinical trial of JANX007 in subjects with metastatic castration-resistant prostate cancer (mCRPC). JANX007 is a prostate-specific membrane antigen (PSMA) directed T cell engager (TCE) and is the first product candidate utilizing Janux’s TRACTr platform to be administered in humans.

 

For further information, refer to the detailed Pancreatic Cancer Unmet Needs, Pancreatic Cancer Market Drivers, and Pancreatic Cancer Market Barriers, click here for Pancreatic Cancer Ongoing Clinical Trial Analysis

 

Pancreatic Cancer Emerging Drugs Profile

 

Pamrevlumab: FibroGen

Pamrevlumab is a potential first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. Pamrevlumab is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD). The U.S. Food and Drug Administration has granted Orphan Drug Designation (ODD), and Fast Track designation to pamrevlumab for the treatment of patients with IPF, LAPC, and DMD.

 

Niraparib: Innovent Biologics

Niraparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP-1 and PARP-2, which play a role in DNA repair. In vitro studies have shown that niraparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis and cell death. Increased niraparib-induced cytotoxicity was observed in tumor cell lines with or without deficiencies in BRCA1/2. Niraparib decreased tumor growth in mouse xenograft models of human cancer cell lines with deficiencies in BRCA1/2 and in human patient-derived xenograft tumor models with homologous recombination deficiency that had either mutated or wild type BRCA1/2. Currently, it is in Phase II stage of clinical trial evaluation to treat pancreatic cancer.

 

CT041: CARsgen Therapeutics

CT041 is an autologous CAR T-cell product candidate against the protein CLDN18.2 that has the potential to be the first-in-class globally. CT041 targets the treatment of CLDN18.2 positive solid tumors with a primary focus on GC/GEJ and PC. CT041 has demonstrated promising therapeutic efficacy and favorable safety in ongoing clinical trials. CARsgen believes that CT041 has the potential to become a backbone therapy for GC/GEJ and PC in the future and benefit a large population of patients worldwide. Currently, it is in Phase I/II stage of clinical trial evaluation to treat pancreatic cancer.

 

APG-1387: Ascentage Pharma

APG-1387 is a high-efficiency and specific inhibitor of a new generation of inhibitor of apoptosis protein (IAP) independently designed and developed by Ascentage Pharma with global intellectual property rights. It mainly induces and accelerates cell apoptosis by simulating the degradation of IAPs by endogenous SMAC molecules process. The company is developing APG-1387 globally, and has completed Phase I dose escalation trials for solid tumors in China and Australia, and is conducting Phase Ib/II clinical trials in combination with pembrolizumab in the United States. Approved to initiate a Phase Ib/II clinical trial in combination with paclitaxel and gemcitabine in the treatment of advanced pancreatic cancer in China. At the same time, the clinical study for the treatment of chronic hepatitis B is being carried out in China, and the phase II clinical study of APG-1387 combined with entecavir in the treatment of chronic hepatitis B is in progress.

 

NGM120: NGM Biopharmaceuticals

NGM120 is an antagonist antibody that binds glial cell-derived neurotrophic factor receptor alpha-like (GFRAL) and inhibits growth differentiation factor 15 (GDF15) signaling. NGM initiated a Phase 2 randomized, single-blind (investigator-blinded), placebo-controlled, multi-center expansion study (PINNACLES) in March 2021 to evaluate NGM120 as a first-line treatment in 60 patients with metastatic pancreatic cancer. In the ongoing study, patients will be randomized to either NGM120 or placebo in combination with gemcitabine/Nab-paclitaxel. The study will evaluate the effects of NGM120 on both cancer and cancer-related cachexia.

 

Pancreatic Cancer Pipeline Therapeutics Assessment

There are approx. 120+ key companies which are developing the therapies for Pancreatic Cancer. The companies which have their Pancreatic Cancer drug candidates in the most advanced stage, i.e. phase III include, FibroGen.

 

Request a sample and discover the recent advances in Pancreatic Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Pancreatic Cancer Treatment Landscape

 

Scope of the Pancreatic Cancer Pipeline Report

 

• Coverage- Global

 

• Pancreatic Cancer Companies- Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Advaxis, Inc., Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc, Arvinas Inc, Epizyme, Regeneron Pharmaceuticals, Veru Inc., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., Janux Therapeutics, Fusion Pharmaceuticals, Corbus Pharmaceuticals, BioXcel Therapeutics, Onxeo S.A, Ayala Pharmaceuticals, HOOKIPA Pharma, Nuvation Bio, Ambrx, enGene, Jemincare, CellVax Therapeutics, POINT Biopharma, Oncternal Therapeutics, Immunic AG, BioNTech SE, and others.

 

• Pancreatic Cancer Pipeline Therapies- Pembrolizumab, Talazoparib, ODM-208, ZEN 3694, EPI-7386, RV 001, Adavosertib, Capivasertib, ADXS31-142, TRC253, Nivolumab, LAE001, BR55, ARV-110, Tazemetostat, REGN5678, VERU-111, Abemaciclib, Cabozantinib, LY01005, Tarlatamab, VT-464, BAY2315497, NX-1207, MBM-02, TAVT-45, FOR46, JNJ-78278343, 64Cu-SAR-bisPSMA, DKN-01, HC-1119, ChAdOx1-MVA 5T4, Onvansertib, GT0918, TNB-585, JANX007, 225Ac-PSMA I&T, CRB-701, BXCL701, AsiDNA, ADXS-504, HB-300, NUV-868, ARX517, JMKX002992, Zilovertamab, IMU-935, BNT112, and others.

 

• Pancreatic Cancer Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Pancreatic Cancer Market Drivers and Pancreatic Cancer Market Barriers, click here @ Pancreatic Cancer Unmet Needs and Analyst Views

 

Table of Content 

1. Introduction
2. Executive Summary
3. Pancreatic Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Pancreatic Cancer – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Pamrevlumab: FibroGen
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Niraparib: Innovent Biologics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. CT041: CARsgen Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. ONC 212: Oncoceutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Pancreatic Cancer Key Companies
21. Pancreatic Cancer Key Products
22. Pancreatic Cancer- Unmet Needs
23. Pancreatic Cancer- Market Drivers and Barriers
24. Pancreatic Cancer- Future Perspectives and Conclusion
25. Pancreatic Cancer Analyst Views
26. Pancreatic Cancer Key Companies
27. Appendix

 

Got Queries? Find out the related information on Pancreatic Cancer Mergers and acquisitions, Pancreatic Cancer Licensing Activities @ Pancreatic Cancer Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/